Clinical trial · Interventional
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell lung cancer. Vaccine production will be attempted on all patients who undergo surgery and meet all inclusion/exclusion criteria.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Non-Small-Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Pulmonary Cancer | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HSPPC-96 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary goal of this trial is to determine if HSPPC-96 can be made from the tumor tissue of patients with resectable non-small cell lung cancer.
Secondary outcomes (1)
- measure
- The secondary goals are to further characterize the safety and efficacy profile, to evaluate disease recurrence in patients, and to evaluate overall survival in patients receiving HSPPC-96.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
This is a summary of criteria. Only the Principal Investigator can determine eligibility. Inclusion Criteria: * Suspected non-small cell lung cancer, Stage IB, Stage II, or Stage IIIA * Tumor size \> 3x3 cm or equivalent to a 9 cm² lesion * Scheduled surgery with curative intent * At least 18 years of age * Must not be pregnant or breast feeding * Agree to not receive any other investigative agent at any time while enrolled in this study Exclusion Criteria: * Previous treatment for non-small cell lung cancer * Clinical signs or symptoms of brain metastases * History of immune suppression or autoimmune disorder * Severe active infection or other serious medical illness, that in the opinion of the Principal Investigator, would prevent study completion * Other malignancies in the past 5 years, except adequately treated in situ cervix carcinoma or non-melanoma skin cancer
References
Publications (0)
Data not yet available